Fina Lladós, new president of Farmaindustria: ‘I will work to generate confidence and make the industry strategic in the economic and social development of Spain’.
The Extraordinary General Assembly on Thursday unanimously elected the CEO of Amgen Iberia to lead the Association for the next two years.
Source: Farmaindustria.es
Fina Lladós will chair Farmaindustria for the next two years. The CEO of the biotech company Amgen was unanimously elected this Thursday at the Extraordinary General Assembly of Farmaindustria to succeed Jesús Ponce, president of the Novartis Group, in the position from October 2022.
The new president of the Association has expressed her willingness to collaborate and listen: ‘I will reach out to all entities that, like us, want health to be a good for society and an opportunity for the country’. She has also shown her commitment to these objectives: ‘I will work to generate confidence and to make the pharmaceutical industry strategic in the economic and social development of Spain’.
He also referred to the ‘unique moment’ that the industry is experiencing, which both the Government and the European Commission – through the ‘Draghi Report’ – has positioned as a strategic sector due to its outstanding contribution to R&D, the balance of trade balance, economic development and the generation of quality employment. In this sense, Lladós called for ‘taking advantage of this unique opportunity with humility, confidence and perseverance’.
Lladós was already vice-president of Farmaindustria and president of LAWG, the Association of American Pharmaceutical Companies operating in Spain.
Lladós will be joined in her mandate by a total of 12 vice presidents: Felipe Pastrana (Abbvie), Lidia Martín (Almirall), David Solanes (ERN), Sergi Aulinas (Gebro), Cristina Henríquez de Luna (Glaxosmithline), Manuel Zafra (Merck), Ana Argelich (Merck Sharp & Dohme), Jesús Ponce (Novartis), Carlos Murillo (Pfizer), Federico Plaza (Roche Farma), Juan López-Belmonte (Rovi), and Raquel Tapia (Sanofi-Aventis).
Source: Farmaindustria.es
The succession takes place in accordance with Farmaindustria’s Bylaws, which establish an alternation at the head of the entity between the groups of companies that make up the Association according to the origin of their capital: national, European/international and American. For the next two years, the Presidency corresponds to the group of companies with American capital.
The new Board of Directors and the new Governing Council of the Association were also constituted at the Assembly, which met extraordinarily in Madrid and by telematic means.
Profile of the new president of Farmaindustria
Fina Lladós graduated in Pharmacy from the University of Barcelona and subsequently completed a Management Development Programme at IESE, a postgraduate degree in Industry Medicine from the Autonomous University of Barcelona and a Master’s Degree in the Pharmaceutical Industry from the Centre for Higher Studies in the Pharmaceutical Industry (Cesif).
With more than 25 years of experience in the pharmaceutical industry, he began his career at Roche and Sanofi-Aventis and has worked at Amgen since 1999. In this company she has developed her career in the R&D area, as well as in the medical and commercial departments, both in Spain and in the company’s European headquarters in Switzerland. Since 2017 she has been the general manager of Amgen Iberia.
